Hello, everyone. Nice to see you again. We hope your weekend was pleasant and enjoyable. Now, though, the routine has returned. What to do first? Grab a cup or two of stimulation and brace yourself for what lies ahead - meetings and deadlines and who knows what? So here are a few items to help you through. Good luck and have a great day...
Lilly's Jan Lundberg Worries About Dropping The Ball (The Indy Star)
DOJ Probes Pfizer Over Rapamune Marketing (Dow Jones)
Germany's Merck Paying $6B For Millipore (Associated Press)
Brain Image Suggests Alzheimer's Drug Works (Reuters)
Astellas Launches Hostile Bid For OSI (TheStreet)
AZ Exercises Merck Option For $647M (Reuters)
Novartis Shareholders Back 'Say On Pay' (Dow Jones)
Medicare Cuts Prompts Doc To Limit Elderly Patients (Bloomberg)
Coffee pix thx to chichcacha flickr creative commons
1 Comment
On the Merck/AstraZeneca deal. The 2012 "Part Two" of that deal is far more fascinating than the widely-expected part one.
This "Deal, Part Two" gives AZ the right to get Nexium® back in 2012 -- for as little as one-half annual sales, or as much as one times annual sales. That is a GREAT deal, by any measure.
In fact, it may be that the current part one announcement ($647 million paid to Merck in April 2010) for smaller products, is a smoke screen for the real value transfer here: the Nexium and Prilosec rights.
Note that the Merck Nexium "pay for delay" deal (with Ranbaxy, concluded in late 2008) is being investigated by the DoJ and FTC, for its allegedly anticompetitive effects.
Namaste